The First Case of Decitabine Successfully in Treatment of Atypical Chronic Myeloid Leukemia with CEBPA Double Mutation
نویسندگان
چکیده
Background: Atypical chronic myeloid leukemia (aCML) treated with decitabine is never reported. Methods: We admitted a 69-year-old man with splenomegaly, hyperleucocytosis, thrombocytopenia and anemia, then morphology, immunology, cytogenetics and molecular biology analysis of bone marrow were performed and the diagnosis of aCML was made. The patient was initially treated with decitabine chemotherapy (20 mg/m2×5 days). The patient achieved complete hematology and morphologic remission after three cycle’s treatment. Results: The data demonstrated that the diagnosis was aCML, which may be misdiagnosed easily. The patient responded very well to decitabine. Conclusion: This case provides evidence that decitabine is effective for therapy in aCML, and demonstrated a new safety and efficacy strategy in the management of other myeloproliferative diseases. Citation: Mao L, You L, Yang M, Li Y, Ye X, et al. (2013) The First Case of Decitabine Successfully in Treatment of Atypical Chronic Myeloid Leukemia with CEBPA Double Mutation. Chemotherapy 2: 114. doi:10.4172/2167-7700.1000114
منابع مشابه
Coexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib: A Case Report
This report describes an 89-year-old woman diagnosed with Philadelphia positive Chronic Myeloid Leukemia in 2007 who was initially treated with 200 mg/day imatinib. The patient demonstrated complete molecular response (CMR) in two tests in 2015 and 2018. During treatment between 2007 and 2019, despite increased dosage of imatinib and switching her therapy to nilotinib, complete hematological r...
متن کاملEpigenetic effects of decitabine on acute lymphoblastic and acute promyelocytic leukemia cells
Background: Decitabine (5-aza-2'-deoxycytidine, DAC) is a deoxycytidine analog currently used as an effective drug against myelodysplastic syndromes and acute myeloid leukemia. Although various studies have pointed out the epigenetic effects of this drug, its epigenetic mechanisms in different leukemic cell lines are not specified. In this lab trial study, possible epigenetic effects of decitab...
متن کاملChronic myeloid leukemia following colon cancer treatment: A case report and literature review
Background: Solid tumors may occur in 3% of the patients with chronic myeloid leukemia (CML). In this paper, we presented a case of CML following treatment of colon cancer. Case Presentation: A 25 year old man was diagnosed of adenocarcinoma of rectosigmoid treated with fluorouracil-based chemotherapy. Following relapse, he received florouracil, oxaliplatin and irinotecan during the next year. ...
متن کاملClinical and Laboratory Findings of Cup-Like Nuclei in Blasts with FLT3 Mutation in Pediatric Acute Myeloid Leukemia: A Case Report
Biologically, Acute myeloid leukemia (AML) is highly heterogenous. AML with cup-like blast morphology variant has been reported to have important role in risk group stratification and treatment implications. In pediatric age group, this morphology and its clinical implication is rarely discussed. Although this morphology variant is not stated in World Health Organization (WHO) classification of...
متن کاملCharacterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
BACKGROUND Dysfunctioning of CCAAT/enhancer binding protein α (C/EBPα) in acute myeloid leukemia can be caused, amongst others, by mutations in the encoding gene (CEBPA) and by promoter hypermethylation. CEBPA-mutated acute myeloid leukemia is associated with a favorable outcome, but this may be restricted to the case of double mutations in CEBPA in adult acute myeloid leukemia. In pediatric ac...
متن کامل